Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 9/2003

01-08-2003 | Review Article

Treatments for Improving Survival of Patients with Prostate Cancer

Authors: Alice K. David, Radhika Khwaja, Dr Gary R. Hudes

Published in: Drugs & Aging | Issue 9/2003

Login to get access

Abstract

Prostate cancer is a heterogeneous disease characterised by a long natural history relative to other solid tumours. With the diagnosis of prostate cancer being made earlier, the emphasis of treatment has shifted from palliation of symptoms to altering disease-related morbidity and mortality and thus improving overall survival.
Treatment of prostate cancer increasingly involves an approach that combines local therapies directed at the primary tumour together with systemic therapies to potentiate their effect and to control subclinical metastatic disease. Patients with localised tumours who are at high risk of relapsing with radiation therapy alone are surviving longer because of the addition of adjuvant hormonal therapy. Although a survival benefit in similar patients undergoing prostatectomy has not yet been established, preliminary results indicate that adjuvant hormonal therapy delays relapse.
Chemotherapy is an effective palliative modality for patients with hormone-refractory metastatic disease, and recently completed phase III trials will determine if chemotherapy can prolong survival for this group. The role of chemotherapy in patients with locally advanced tumours is also being investigated in randomised clinical trials.
Because bone is the dominant site of metastases for most patients with prostate cancer, the development of therapies that can slow tumour growth specifically within bone is a logical strategy. Bisphosphonates and bone-targeted radionuclides are two such approaches that have shown encouraging results even in the most advanced stages of the disease.
Although one can now reasonably hypothesise that survival has improved because of recent therapeutic advances, it remains to be conclusively established that cytotoxic or other systemic therapy can extend survival of patients with prostate cancer. Only the results of ongoing randomised trials can definitely establish that more patients with locally advanced and metastatic prostate cancer are living longer.
Literature
1.
2.
Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281(17): 1591–7PubMedCrossRef
3.
Hussain MH, Crawford ED. Androgen deprivation strategies for metastatic prostate cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P, editors. Principles and practice of genitourinary oncology. Philadelphia (PA): Lippincott-Raven, 1996: 591
4.
Greene FL, Page DL, Fleming ID, et al., editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer Verlag, 2002
5.
Veterans Administration Cooperative Research Group. Histologic grading and clinical staging of prostatic carcinoma. In: Tennenbaum M, editor. Urologic oncology: the prostate. Philadelphia (PA): Lea and Fibiger, 1977: 171–4
6.
Partin AW, Kattan MW, Subong ENP, et al. Combination of PSA, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997 May 14; 277(18): 1445–51PubMedCrossRef
7.
D’Amico AV, Whittington R, Malkowicz SB, et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166(6): 2185–8PubMedCrossRef
8.
Smith DS, Catalona WJ. The nature of prostate cancer detected through PSA based screening. J Urol 1994 Nov; 152 (5 pt 2): 1732–6PubMed
9.
Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242–8PubMedCrossRef
10.
Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer: multi-institutional pooled analysis. JAMA 1996 Aug 28; 276(8): 615–9PubMedCrossRef
11.
Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002 Aug 15; 20(16): 3376–85PubMedCrossRef
12.
D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002 Jul 15; 95(2): 281–6PubMedCrossRef
13.
Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281(17): 1598–604PubMedCrossRef
14.
Hanks GE, Hanlon AL. Dose escalation with 3D conformai treatment: five year outcomes, treatment optimization and future directions. Int J Radiat Oncol Biol Phys 1998; 41(3): 501–10PubMedCrossRef
15.
Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the MD Anderson Phase III Randomized Trial. Int J Radiat Oncol Biol Phys 2002; 53(5): 1097–105PubMedCrossRef
16.
Hanks GE, Hanlon AL, Pinover WH, et al. Survival advantage for prostate cancer patients treated with high dose three dimensional conformai radiotherapy. Cancer J Sci Am 1999; 5(3): 152–8PubMed
17.
Pollack A, Zagars GK, Rosen II. Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. Semin Oncol 1999; 26(2): 150–61PubMed
18.
Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002; 167: 112–6PubMedCrossRef
19.
Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001 Aug; 50(5): 1243–52PubMedCrossRef
20.
Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol 1997; 15: 1013–21PubMed
21.
Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337(5): 295–300PubMedCrossRef
22.
Hanks GE, Lu J, Machtay M, et al. RTOG Protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate [abstract 1284]. Proc Am Soc Clin Oncol 2000 May 20–23; 19: 327a
23.
Zincke H, Bergstralh EJ, Larson-Keller JJ, et al. Stage Dl prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: evidence for favorable survival in patients with DNA diploid tumors. Cancer 1992; 70(1 Suppl.): 311–23PubMedCrossRef
24.
Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341(24): 1781–8PubMedCrossRef
25.
See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2001; 168(2): 429–35CrossRef
26.
Zagars GK, Pollack A. Kinetics of Serum PSA after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997; 44(3): 213–21PubMedCrossRef
27.
Huggins C, Hodges CV. Studies on prostatic cancer I: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7
28.
Mcleod D, Zinner N, Gleason D, et al. Abarelix-depot vs leuprolide acetate for prostate cancer: results of multi-institutional, randomized, phase III study in 271 patients [abstract 1306]. Proc Am Soc Clin Oncol 2000 May 20–23; 19: 332a
29.
Laufer M, Denmeade SR, Sinabaldi VJ, et al. Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000; 164(1): 3–9PubMedCrossRef
30.
Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036–42PubMedCrossRef
31.
Crook JM, Szumacher E, Malone S, et al. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53(3): 530–4PubMedCrossRef
32.
Small EJ, Vogelzang NJ. Second line hormonal treatment for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15(1): 382–8PubMed
33.
Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected advanced prostate cancer patients. Cancer 1995; 76(8): 1428–34PubMedCrossRef
34.
Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149: 607–9PubMed
35.
Kucuk O, Fisher E, Moinpour CM, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group Study (SWOG 9235). Urology 2001 Jul; 58(1): 53–8PubMedCrossRef
36.
Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001 Jan 1; 19(1): 62–71PubMed
37.
Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate cancer. Cancer 2000 Dec 15; 89: 2570–6PubMedCrossRef
38.
Small EJ, Halabi S, Picus J, et al. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583 [abstract 695]. Proc Am Soc Clin Oncol 2001 May 12–15; 20: 174a
39.
Dawson NA, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 2000 Feb 15; 88(4): 825–34PubMedCrossRef
40.
Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000 Nov 11; 18(21): 3595–603PubMed
41.
Scher HI, Libertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural vs treated history of disease. J Clin Oncol 1997; 15: 2928–38PubMed
42.
Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone + prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14(6): 1756–64PubMed
43.
Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 1999; 17: 2506–13PubMed
44.
Tew KD, Glusker JP, Hartley-Asp, et al. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther 1992; 56(3): 323–39PubMedCrossRef
45.
Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001; 15(30): 525–45PubMedCrossRef
46.
Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network Phase III Trial. J Clin Oncol 1999; 17: 3160–6PubMed
47.
Hudes G, Ross E, Roth B, et al. Improved survival for patients with hormone-refractory prostate cancer receiving estramustine-based antimicrotubule therapy: final report of a Hoosier Oncology Group and Fox Chase Network phase III trial comparing vinblastine and vinblastine plus oral estramustine phosphate [abstract 704]. Proc Am Soc Clin Oncol 2002 May 18–21; 21: 177a
48.
Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997 Sep; 15(9): 3156–63PubMed
49.
Hudes GR, Manola J, Conroy T, et al. Phase II study of weekly paclitaxel by 1 - hour infusion plus reduced-dose oral estramustine in metastatic hormone-refractory prostate carcinoma: a trial of the Eastern Cooperative Oncology Group[abstract 697]. Proc Am Soc Clin Oncol 2001 May 12–15; 20: 175a
50.
Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001 May 1; 19(9): 2509–16PubMed
51.
Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001 Jan 1; 19(1): 44–53PubMed
52.
Smith DC, Esper P, Strawderman M, et al. Phase II trial of oral estramustine, oral etoposide and IV paclitaxel in hormone refractory prostate cancer. J Clin Oncol 1999; 17: 1664–71PubMed
53.
Hudes G. Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs 2002; 20(2): 159–72PubMedCrossRef
54.
Nelson JB, Carducci MA, Padley RJ, et al. The Endothelin-A receptor antagonist Atrasentan (ABT-627) reduces skeletal remodeling activity in men with advanced, hormone refractory prostate cancer [abstract 12]. Proc Am Soc Clin Oncol 2001 May 12–15; 20: 4a
55.
Carducci MA, Nelson JB, Padley RJ, et al. The Endothelin-A receptor antagonist ABT-627 delays clinical progression in hormone refractory prostate cancer: a multinational, randomized, double-blind, placebo controlled trial [abstract 694]. Proc Am Soc Clin Oncol 2001 May 12–15; 20: 174a
56.
Scher HI, Sarkis A, Reuter V, et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995; 1(5): 545–50PubMed
57.
Herbst RS, Maddox A, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002 Sep 15; 20(18): 3815–25PubMedCrossRef
58.
Baselga J, Rischin M, Ranson H, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types. J Clin Oncol 2002 Nov 1; 19(21): 4292–302CrossRef
59.
Hildalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267–79
60.
Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 12: 4885–92
61.
Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59: 803–6PubMed
62.
Mark HFL, Feldman D, Das S, et al. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol 1999; 66: 170–8PubMedCrossRef
63.
Kallakury BVS, Sheehan CE, Ambros RA, et al. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 1998; 16: 1302–9PubMed
64.
Ye D, Mendelsohn J, Fan Z, et al. Androgen and epidermal growth factor down- regulate cyclin-dependent kinase inhibitor p27Kipl and co-stimulate proliferation of MDA Prostate cancer 2a and MDA Prostate cancer 2b prostate cancer cells. Clin Cancer Res 1999; 5: 2171–7PubMed
65.
Yang X, Jia X, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without chemotherapy. Cancer Res 1999; 59: 1236–43PubMed
66.
Ko Y-J, Small EJ, Kabbinavar F, et al. A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 800–5PubMed
67.
Uehara H, Kim SJ, Karashima T, et al. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice [abstract 2192]. Proc Am Assoc Cancer Res 2001; 42: 18
68.
Bander NH, Trabulski EJ, Yao D, et al. Phase I radioimmunotherapy trials of humanized monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen (PSMAext) radiolabeled with 90yttrium or 177lutetium in advanced prostate cancer [abstract 18]. Proc Am Soc Clin Oncol 2002; 21: 5a
69.
Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18(23): 3894–903PubMed
70.
Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6(15): 1632–8PubMed
71.
Simons J, Nelson W, Nemunaitis J, et al. Phase II trials of a GMCSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer [abstract 729]. Proc Am Soc Clin Oncol 2001 May 18–21; 21: 183a
72.
Slovin S, Ragupathi G, Fernandez C, et al. A bivalent vaccine containing glycosylated MUC-2-KLH and globo H-KLH-conjugates using a new semi-synthetic saponin immunological adjuvant GP1-0100, in biochemically relapsed prostate cancer [abstract 781]. Proc Am Soc Clin Oncol 2001 May 18–21; 21: 196a
73.
Kaufman HL, Wang W, et al. Prime/boost vaccination using poxviruses expressing PSA in D0 prostate cancer: preliminary results of ECOG 7897, a randomized phase II clinical trial [abstract 12]. Proc Am Soc Clin Oncol 2001 May 18–21; 21: 196a
74.
Urwin GH, Percival RC, Harris S, et al. Generalized increase in bone resorption in carcinoma of the prostate. Br J Urol 1985 Dec; 57(6): 721–3PubMedCrossRef
75.
Rodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001 Aug 1; 19: 3562–71
76.
Dougherty KM, Blomme EAG, Koh AJ, et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res 1999 Dec 1; 59: 6015–22PubMed
77.
Bryden AA, Hoyland JA, Freemont AJ, et al. Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br J Cancer 2002 Feb 1;86(3): 322–5PubMedCrossRef
78.
Okamoto M, Lee C, Oyasu R, et al. Interleukin-6 as a paracrine and autocrine growth factor in prostatic carcinoma cells in vitro. Cancer Res 1997 Jan 1; 57(1): 141–6PubMed
79.
Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000 Jul; 6(7): 2702–6PubMed
80.
Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000 Mar 1; 88(5): 1092–0CrossRef
81.
Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events: Myeloma Aredia Study Group. J Clin Oncol 1998 Feb; 16(2): 593–602PubMed
82.
Dearnaley DP, Sydes MR. Preliminary evidence that oral Clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC PrO5 Trial [abstract 693]. Proc Am Soc Clin Oncol 2001 May 12–15; 20: 174a
83.
84.
Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001 Sep 27; 345(13): 948–55PubMedCrossRef
85.
Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001 Sep 15; 92(6): 1444–50PubMedCrossRef
86.
Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994 Apr; 31(1): 33–40PubMedCrossRef
87.
Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase III trial to evaluate the efficacy of Strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant, metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993 Apr 2; 25(5): 805–13PubMedCrossRef
88.
Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind, placebo-controlled clinical trial. J Clin Oncol 1998 Apr; 16(4): 1574–81PubMed
89.
Tu S-M, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001 Feb 3; 357(9253): 336–41PubMedCrossRef
Metadata
Title
Treatments for Improving Survival of Patients with Prostate Cancer
Authors
Alice K. David
Radhika Khwaja
Dr Gary R. Hudes
Publication date
01-08-2003
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 9/2003
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200320090-00005

Other articles of this Issue 9/2003

Drugs & Aging 9/2003 Go to the issue

Review Article

Autoimmune Bullous Dermatoses in the Elderly

Therapy In Practice

Vitreous Haemorrhage in Elderly Patients

Original Research Article

NSAID and Aspirin Use by the Elderly in General Practice

Leading Article

Quality Use of Medicines in Aged-Care Facilities in Australia

Leading Article

Clinical and Economic Issues in the Treatment of Advanced Breast Cancer with Bisphosphonates
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits